Vanda Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Vanda Pharmaceuticals Inc. on May 22, 2009. The filing discloses the execution of new employment agreements with two senior officers: Stephanie R. Irish (Acting Chief Financial Officer) and John J. Feeney, III, MD (Acting Chief Medical Officer).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation terms.
Material Changes and Compensation Details
Effective May 22, 2009, the Company entered into new agreements with the following terms:
- Stephanie R. Irish (Acting CFO):
- Base Salary: Not less than $200,000 annually.
- Annual Incentive Bonus: 25% of base salary.
- Equity: Option to purchase 95,000 shares at $12.55 per share, vesting monthly over four years.
- Severance: Upon termination without cause or for good reason, the Company must pay 12 months of base salary, the target bonus, and 12 months of health benefits, contingent on a written release.
- John J. Feeney, III, MD (Acting CMO):
- Base Salary: Not less than $270,000 annually.
- Annual Incentive Bonus: 25% of base salary.
- Equity: Option to purchase 95,000 shares at $12.55 per share, vesting monthly over four years.
- Severance: Upon termination without cause or for good reason, the Company must pay 12 months of base salary, the target bonus, and 12 months of health benefits, contingent on a written release.
Both officers also entered into indemnification agreements consistent with those held by other executive officers.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, or general risk factors. The primary contingency noted is the acceleration of equity vesting upon a change in control (24 months for Ms. Irish; full acceleration for Dr. Feeney).
Key Facts for Investor Verification
- Verify the total number of shares outstanding to assess the dilution impact of the 190,000 new options granted.
- Confirm the Company's current cash position to evaluate its ability to fund the potential severance obligations (up to 12 months of salary plus bonus for two executives).
- Review the 2006 Equity Incentive Plan to ensure sufficient shares remain available for these grants.
- Monitor the status of the "Acting" titles for the CFO and CMO to determine if permanent appointments are imminent.